Cue Biopharma, Inc. CUE
Regular-session close
After hours · Nov 19, 7:50 PM ET
- YTD
- -50.82%
- 1 year
- -74.14%
5D -13.19 (-74.56%)
- Market cap
- 37.62M
- Revenue (ttm)
- 8.29M
- EPS (ttm)
- -27.80
- Shares out
- 63.35M
- Forward P/E
- -1.79
- YTD return
- -50.82%
- 1-year return
- -74.14%
- 50-day average
- 1.31
- Volume
- 2.06M
- Avg volume
- 519.96K
- Open
- 4.55
- Previous close
- 4.76
- Day's range
- 3.85 – 5.16
- 52-week range
- 2.83 – 45.50
- Beta
- 1.80
- Price target
- 3.60 (-20.0%)
Key statistics
- 200-day average
- 1.26
- Enterprise value
- 41.79M
- Price / sales
- 7.94
- Price / book
- 1.32
- Revenue growth
- 92.30%
- Free cash flow
- -20.00M
- Total cash
- 30.03M
- Total debt
- 11.26M
- Return on equity
- -138.87%
- Short % of float
- 2.98%
Fundamental scorecard
9 of 25 checks passed on CUE’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.17 | +0.03 | +15.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | -0.20 | +0.09 | +31.03% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.30 | -0.25 | +0.05 | +16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Apr 8, 2024 | Dec 1, 2023 | 0.00 | -0.28 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2024 | Stifel | main | Buy | Buy |
| Jul 26, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jul 26, 2024 | Piper Sandler | main | Overweight | Overweight |
| Apr 9, 2024 | Stifel | main | Buy | Buy |
| Apr 9, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 3, 2024 | Piper Sandler | reit | Overweight | Overweight |
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cuebiopharma.com
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings B. Riley Securities Reiterates Buy on Cue Biopharma, Lowers Price Target to $25
12 Health Care Stocks Moving In Tuesday's Intraday Session
S&P 500 Down 1%; Disney Posts Upbeat Earnings
Dow Falls Over 200 Points; US Retail Sales Rise 0.2% In October Cue Biopharma Q3 EPS $(4.74) Misses $(2.24) Estimate, Sales $132.000K Miss $1.033M Estimate
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
12 Health Care Stocks Moving In Wednesday's After-Market Session
Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Your note
Sign in to keep a note on CUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KIENER PETER A | Director | Sale | Mar 22, 2023 | 357 |
| PASSERI DANIEL R | Chief Executive Officer | Purchase | Dec 15, 2024 | 164,578 |
| SURI ANISH | President | Purchase | Aug 24, 2023 | 135,638 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bleichroeder LP | 7.89% | 4,997,240 | 5.20M | Sep 29, 2024 |
| Slate Path Capital, LP | 3.79% | 2,402,455 | 2.50M | Sep 29, 2024 |
| Vanguard Group Inc | 3.21% | 2,031,421 | 2.11M | Sep 29, 2024 |
| Blackrock Inc. | 0.90% | 570,975 | 593.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.80% | 508,827 | 529.18K | Sep 29, 2024 |
| Robertson Stephens Wealth Management, LLC | 0.76% | 478,500 | 497.64K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.13% | 1,347,078 | 1.40M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.94% | 597,569 | 621.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 276,050 | 287.09K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.17% | 110,814 | 115.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 88,916 | 92.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 66,386 | 69.04K | Oct 30, 2024 |
